NCT00144105终止2 期
A Randomised, Open Label, Active Controlled Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir Plus 100 mg or 200 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Comparison to 400 mg Lopinavir Plus 100 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Antiretroviral Therapy Naive Patients for 48 With Extension up to 156 Weeks
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 562
- 试验地点
- 81
- 主要终点
- The primary endpoint is the proportion of treatment responders at 48 weeks. A treatment responder is a patient with a viral load (VL) less than 50 copies/mL measured at two consecutive visits without prior rebound or change of ARV therapy.
研究概览
简要总结
Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavir (RTV) versus an active control arm (Lopinavir / RTV) in antiretroviral (ARV) therapy naïve HIV-1 infected patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent prior to trial participation.
- •HIV-1 infected males or females >= 18 years of age.
- •No previous ARV therapy.
- •Any CD4+ T lymphocyte count < 500 cells / µl.
- •HIV-1 viral load >= 5000 copies/mL at screening.
- •Screening laboratory values that indicate adequate baseline organ function.
- •A prior AIDS defining event is acceptable as long as it has resolved or the subject has been on stable treatment (e.g. opportunistic infection; no ARV) for at least 2 weeks before screening
排除标准
- •Female patients of child-bearing potential who:
- •have a positive serum pregnancy test at screening or during the study,
- •are breast feeding,
- •are planning to become pregnant
- •Use of investigational medications within 30 days before study entry or during the trial
结局指标
主要结局
The primary endpoint is the proportion of treatment responders at 48 weeks. A treatment responder is a patient with a viral load (VL) less than 50 copies/mL measured at two consecutive visits without prior rebound or change of ARV therapy.
次要结局
- Further analyses to evaluate the primary endpoint at 24, 96, and 156 weeks. Secondary endpoints include proportion of patients with VL< 400 copies/mL, change from baseline in CD4+ cell counts at each visit, time to a new CDC class C progression event.
研究者
研究点 (81)
Loading locations...
相似试验
已完成
1 期
Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy VolunteersHealthyNCT02251873Boehringer Ingelheim50
终止
1 期
Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult VolunteersHealthyNCT02245438Boehringer Ingelheim52
终止
3 期
Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PIHIV InfectionsNCT00517192Boehringer Ingelheim40
已完成
3 期
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)HIV InfectionsNCT00054717Boehringer Ingelheim630
已完成
1 期
Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy VolunteersHealthyNCT02251145Boehringer Ingelheim49